Data Science to Accelerate Drug Discovery with Artificial Intelligence and Machine Learning, Says Frost & Sullivan

For further information on this analysis, please visit: http://frost.ly/4l2. "Applying data science tools in healthcare, especially for drug discovery, has a huge potential to systematically change the entire existing practices and methods," said Aarthi Janakiraman, Technical Insights Research Manager at Frost & Sullivan. "Additionally, pharmaceutical companies and hospitals are adopting this system rapidly, and its application is going to be established in all branches of healthcare." Janakiraman added: "Integrating AI and ML methods into drug discovery pipelines would cut down cost and time, and increase the efficiency of the entire research and development (R&D) process. Going forward, big pharma and mid-sized biotech companies can benefit by partnering with core AI startups and reducing the costs involved in setting up their own capabilities."